7101/13381US=6 / Quimioterapia
Airley R. Novel anticancer agents. In: ___. Cancer chemotherapy: basic science to the clinic. New Jersey: John Wiley & Sons, 2009. p. 125-65. ISBN 978-0-470-09254-5.

AGENTES ANTICANCERIGENOS; MANIPULACAO GENETICA DE LINHAS CELULARES; CELULAS TUMORAIS SHEROIDS; DROGAS DE CHUMBO; TRIAGEM; ATIVIDADE ANTICANCERIGENA IN VITRO; XENOENXERTOS TUMORES


7102/13381US=6 / Quimioterapia
Airley R. Clinical trials. In: ___. Cancer chemotherapy: basic science to the clinic. New Jersey: John Wiley & Sons, 2009. p. 167-75. ISBN 978-0-470-09254-5.

EVOLUCAO NO TRATAMENTO; ENSAIOS CLINICOS; AVALIACAO DA VASCULARIZACAO; ANGIOGENESE PELA TECNOLOGIA DE MEDICINA NUCLEAR


7103/13381US=6 / Quimioterapia
Airley R. Tumour hypoxia. In: ___. Cancer chemotherapy: basic science to the clinic. New Jersey: John Wiley & Sons, 2009. p. 177-98. ISBN 978-0-470-09254-5.

HIPOXIA TUMORAL; DROGAS BIORREDUTIVA


7104/13381US=6 / Quimioterapia
Airley R. Antiangiogenic and antivascular agents. In: ___. Cancer chemotherapy: basic science to the clinic. New Jersey: John Wiley & Sons, 2009. p. 199-216. ISBN 978-0-470-09254-5.

AGENTES ANTIANGIOGENICOS; AGENTES ANTIVASCULAR; HISTORIA DA ANGIOGENESE; ANTI-ANGIOGENICOS; TALIDOMIDA; ANTICORPOS; AGENTES ANTIANGIOGENICOS; AGENTES PERTURBADORES


7105/13381US=6 / Quimioterapia
Airley R. Tyrosine kinase inhibitors. In: ___. Cancer chemotherapy: basic science to the clinic. New Jersey: John Wiley & Sons, 2009. p. 217-23. ISBN 978-0-470-09254-5.

INIBIDORES DA QUINASE DE TIROSINA; NAO-RECEPTOR INIBIDORES DE TIROSINA


7106/13381US=6 / Quimioterapia
Airley R. Ras inhibitors. In: ___. Cancer chemotherapy: basic science to the clinic. New Jersey: John Wiley & Sons, 2009. p. 225-8. ISBN 978-0-470-09254-5.

INIBIDORES DE RAS


7107/13381US=6 / Quimioterapia
Airley R. Inhibitors of the AKT/PKB pathway. In: ___. Cancer chemotherapy: basic science to the clinic. New Jersey: John Wiley & Sons, 2009. p. 229-31. ISBN 978-0-470-09254-5.

INIBICAO DA VIA AKT/PKB


7108/13381US=6 / Quimioterapia
Airley R. Targeting stress proteins: HSP90 inhibitors. In: ___. Cancer chemotherapy: basic science to the clinic. New Jersey: John Wiley & Sons, 2009. p. 233-6. ISBN 978-0-470-09254-5.

SEGMENTACAO PROTEINAS DE ESTRESSE; INIBIDORES HSP90


7109/13381US=6 / Quimioterapia
Airley R. The proteasome. In: ___. Cancer chemotherapy: basic science to the clinic. New Jersey: John Wiley & Sons, 2009. p. 237-43. ISBN 978-0-470-09254-5.

PROTEASSOMA; PROTEASSOMA. NOVAS DROGAS


7110/13381US=6 / Quimioterapia
Airley R. Checkpoint protein kinases as novel targets - mammalian target of rapamycin (mTOR). In: ___. Cancer chemotherapy: basic science to the clinic. New Jersey: John Wiley & Sons, 2009. p. 245-8. ISBN 978-0-470-09254-5.

CHECKPOINT; PROTEINAS QUINASES; MTOR; ALVO DA RAPAMICINA EM MAMIFEROS; ATIVACAO DE MTOR; ANTICANCERIGENOS ALVO MTOR


7111/13381US=6 / Quimioterapia
Airley R. Telomerase. In: ___. Cancer chemotherapy: basic science to the clinic. New Jersey: John Wiley & Sons, 2009. p. 249-54. ISBN 978-0-470-09254-5.

TELOMERASE


7112/13381US=6 / Quimioterapia
Airley R. Histone deacetylase: an epigenetic drug target. In: ___. Cancer chemotherapy: basic science to the clinic. New Jersey: John Wiley & Sons, 2009. p. 255-63. ISBN 978-0-470-09254-5.

INIBIDORES DE HDAC; HISTONA DEACETILASE; DROGA EPIGENETICA; HDAC; EMBALAGEM DE DNA


7113/13381US=6 / Quimioterapia
Airley R. Pharmaceutical problems in cancer chemotherapy. In: ___. Cancer chemotherapy: basic science to the clinic. New Jersey: John Wiley & Sons, 2009. p. 265-80. ISBN 978-0-470-09254-5.

PROBLEMAS FARMACEUTICOS EM QUIMIOTERAPIA; MANIFESTACAO DE TOXICIDADE; REGIME DE TOXICIDADE; RESISTENCIA A DROGAS; COMPLICACOES FARMACEUTICAS


7114/13381US=6 / Quimioterapia
Airley R. Oncology pharmacy at home and abroad. In: ___. Cancer chemotherapy: basic science to the clinic. New Jersey: John Wiley & Sons, 2009. p. 281-2. ISBN 978-0-470-09254-5.

ONCOLOGIA FARMACIA EM CASA E NO EXTERIOR


7115/13381US=6 / Quimioterapia
Airley R. Practice exam questions. In: ___. Cancer chemotherapy: basic science to the clinic. New Jersey: John Wiley & Sons, 2009. p. 283-98. ISBN 978-0-470-09254-5.

QUIMIOTERAPIA. QUESTOES PRATICAS


7116/13381US=22 / Urologia
Junior Kaelin WG, Geoge DJ. The molecular biology of kidney cancer and its clinical translation into treatment strategies. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 79-97. ISBN 978-1-58829-737-2.

VON HIPPEL-LINDAU; HIPOXIA; ANGIOGENESE; HIF; VEGF; KDR; MTOR


7117/13381US=22 / Urologia
Ramakrishnan V, Bhaskar V, Fox M, Wilson K, Cheville JC, Finck BA. Integrin &*945;5&*946;1 as a noveltherapeutic target in renal cancer. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 195-209. ISBN 978-1-58829-737-2.

INTEGRINAS NA ANGIOGENESE; TERAPIA ANTI-ANGIOGENICA; CANCER RENAL &*945;5&*946;1; VOLOCIXIMAB


7118/13381US=22 / Urologia
Peruzzi B, Lattouf JB, Bottaro DP. The role of hepatocyte growth factor pathway signaling in renal cell carcinoma. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 321-34. ISBN 978-1-58829-737-2.

FATOR DE CRESCIMENTO HEPATOCITO; C-MET; CARCINOMA DE CELULAS RENAIS; MECANISMOS ONCOGENICOS; DESENVOLVIMENTO DROGA CONTRA O CANCER


7119/13381US=22 / Urologia
Mizutani Y, kawauchi A, Bonavida B, Miki T. Smac/DIABLO: a proapoptotic molecular target in renal cell cancer. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 335-46. ISBN 978-1-58829-737-2.

CARCINOMA DE CELULAS RENAIS; SMAC / DIABLO; PROGNOSTICO; APOPTOSE; CISPLATINA; XIAP; RCC; TRAIL


7120/13381US=9 / Quimioterapia
Cross HS, Nittke T. Selected vitamins: vitamina D. In: Knasmüller S, DeMarini DM, Johnson I, Gerhäuser C. Chemoprevention of cancer and DNA damage by dietary factors. Weinheim: Wiley-VCH, 2009. p. 393-402. ISBN 978-3-527-32058-5.

PREVENCAO DO CANCER; VITAMINA D; SINTESE DA VITAMINA D; PROPRIEDADES FISICO-QUIMICAS; BIODISPONIBILIDADE; METABOLISMO; MECANISMOS PROTETORES; PROCESSAMENTO DE ALIMENTOS; NUTRICAO


Primeira | Anterior | Próxima | Última